A5016085898- Nanoparticle-Based Drug Delivery
- Immunotherapy and Immune Responses
- Hepatocellular Carcinoma Treatment and Prognosis
- Neuroendocrine Tumor Research Advances
- Cancer, Hypoxia, and Metabolism
- Extracellular vesicles in disease
- Glycosylation and Glycoproteins Research
- Monoclonal and Polyclonal Antibodies Research
- Advanced biosensing and bioanalysis techniques
- Nanoplatforms for cancer theranostics
- Metabolism, Diabetes, and Cancer
- Advanced Manufacturing and Logistics Optimization
- Cancer Mechanisms and Therapy
- RFID technology advancements
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Cancer Immunotherapy and Biomarkers
- MicroRNA in disease regulation
- Liver Disease Diagnosis and Treatment
- Complement system in diseases
- Blood groups and transfusion
- Characterization and Applications of Magnetic Nanoparticles
- Polymer Surface Interaction Studies
- Flexible and Reconfigurable Manufacturing Systems
- CAR-T cell therapy research
Centro di Riferimento Oncologico
2019-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2025
University of Trieste
2019-2025
University of Rome Tor Vergata
2013
Drug delivery strategies using chitosan nanobubbles (CS-NBs) could be used to reduce drug side effects and improve outcomes in hepatocellular carcinoma (HCC) treatment. To enhance their action, a targeting agent, such as the humanized anti-GPC3 antibody GC33 (condrituzumab), attached surface. Here, we investigated use of idarubicin-loaded CS-NBs for HCC treatment GC33-derived minibody (that named 4A1) CS-NB delivery. Various formulations were prepared with or without 4A1 conjugation...
Background and Objectives: The administration of oral vaccines offers a potential strategy for cancer immunotherapy; yet, the development effective platforms continues to pose difficulty. This study examines Escherichia coli Nissle 1917 (EcN) as microbial vector precise delivery Glypican-1 (GPC1), tumor-associated antigen significantly overexpressed in pancreatic ductal adenocarcinoma (PDAC).To evaluate effectiveness EcN GPC1 assess its an vaccination platform immunotherapy. Materials...
MicroRNAs represent interesting targets for new therapies because their altered expression influences tumor development and progression. miR-17 is a prototype of onco-miRNA, known to be overexpressed in B-cell non-Hodgkin lymphoma (B-NHL) with peculiar clinic-biological features. AntagomiR molecules have been largely studied repress the regulatory functions up-regulated onco-miRNAs, but clinical use mainly limited by rapid degradation, kidney elimination poor cellular uptake when injected as...
Background Recently, we developed AT101, an IgM-class mouse monoclonal antibody directed against glypican-1 (GPC1), a proteoglycan that can be considered as useful target for glioblastoma multiforme (GBM) treatment being specifically and highly expressed on GBM cell surface. Here, proposed the use of AT101 targeting agent in drug delivery nanoplatfom to effectively deliver chitosan nanobubbles (NBs) treatment.
Current literature agrees that one of the main results obtained by adopting RFID lies in an improved efficiency increase material handling operations, especially regarding reductions time required to perform certain procedural steps. Howeve
Although extensive advancements have been made in treatment against hepatocellular carcinoma (HCC), the prognosis of HCC patients remains unsatisfied. It is now clearly established that epigenetic changes act as a driver human tumors. This study exploits deregulation to define novel prognostic model for monitoring progression HCC. We analyzed genome-wide DNA methylation profile 374 primary tumor specimens using Illumina 450 K array data from The Cancer Genome Atlas. initially used...
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with a very low survival rate at 5 years. The use chemotherapeutic agents results in only modest prolongation and generally associated occurrence toxicity effects. Antibody-based immunotherapy has been proposed for treatment PDAC, but its efficacy so far proved limited. proteoglycan glypican-1 (GPC1) may be useful immunotherapeutic target because it highly expressed on surface PDAC cells,...
Abstract Background: MicroRNAs represent interesting targets for new therapies because their altered expression influences tumor development and progression. miR-17 is a prototype of onco-miRNA, known to be overexpressed in B-cell non-Hodgkin lymphoma (B-NHL) with peculiar clinic-biological features. AntagomiR molecules have been largely studied repress the regulatory functions up-regulated onco-miRNAs, but clinical use mainly limited by rapid degradation, kidney elimination poor cellular...